DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Barclays Initiates Coverage On Syndax Pharmaceuticals with Overweight Rating, Announces $15 Price Target

Barclays analyst Peter Lawson initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight rating and a $15 price target.

Benzinga · 03/04/2020 10:28

Barclays analyst Peter Lawson initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight rating and a $15 price target.